Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - A five-year update

Expert Opinion on Biological Therapy

Volumn 13, Issue 11, 2013, Pages 1599-1611

  Poddubnyy, Denis ^b   Rudwaleit, Martin ^a  

^a Endokrinologikum Berlin   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adalimumab; Ankylosing spondylitis; Nonradiographic axial spondyloarthritis; Tumor necrosis factor

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; SARILUMAB; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADD ON THERAPY; ANKYLOSING SPONDYLITIS; ARTICLE; BONE DESTRUCTION; CANDIDIASIS; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LUPUS LIKE SYNDROME; LYMPHOMA; NON MELANOMA SKIN CANCER; NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS; OPPORTUNISTIC INFECTION; PSORIASIS; SARCOIDOSIS; SPONDYLARTHRITIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; DOUBLE-BLIND METHOD; DRUG APPROVAL; EUROPEAN UNION; HUMANS; INFECTION; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPINE; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84885591644     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.839653     Document Type: Article

References (90)

1. Rudwaleit M, Landewe R, van Der Heijde D, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): Classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009á68(6):770-6
2. Rudwaleit M, van Der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann Rheum Dis 2009á68(6):777-83
3. Rudwaleit M, van Der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011á70(1):25-31
4. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: Do we need new criteria? Arthritis Rheum 2005á52(4):1000-8
5. Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondylarthritis: Results from the german spondyloarthritis inception cohort. Arthritis Rheum 2009á60(3):717-27
6. Kiltz U, Baraliakos X, Karakostas P, et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken) 2012á64(9):1415-22
7. Braun J, van Den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011á70(6):896-904
8. Braun J, Zochling J, Baraliakos X, et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: A multicentre randomised controlled trial. Ann Rheum Dis 2006á65(9):1147-53
9. Haibel H, Brandt HC, Song IH, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: A 16-week open-label trial. Ann Rheum Dis 2007á66(3):419-21
10. Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005á64(1): 124-6
11. van Der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011á70(6):905-8
12. Poddubnyy D. Axial spondyloarthritis: Is there a treatment of choice? Ther Adv Musculoskelet Dis 2013á5(1):45-54
13. Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: Results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 2013
14. Baeten D, Sieper J, Emery P, et al. The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum 2010 62(12):3840
15. Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four-week clinical trial. Arthritis Rheum 2010 62(5):1290-7
16. Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: An open-label, 24-week pilot study. Ann Rheum Dis 2011á70(6):1108-10
17. Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005á64(2):296-8
18. Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: Results of randomised, placebo-controlled trials. Ann Rheum Dis 2013
19. Sieper J, Inman R, Badalamenti S, et al. Sarilumab for the treatment of ankylosing spondylitis: Results of a phase 2, randomized, double-blind, placebo-controlled, international study (ALIGN). Ann Rheum Dis 2012á71(Suppl3):111
20. Sieper J, Rudwaleit M, Braun J. Adalimumab for the treatment of ankylosing spondylitis. Expert Opin Pharmacother 2007á8(6):831-8
21. Adalimumab (Humira) label approved by FDA on 13.05.2013. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125057s310lbl.pdf
22. Product information: Adalimumab (Humira). last updated 15.04.2013 Available from: Http://www.emea.europa. eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000481/WC500050870.pd
23. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994á21(12):2286-91
24. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008á117(2):244-79
25. Haibel H, Rudwaleit M, Brandt HC, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006á54(2):678-81
26. van Der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984á27(4):361-8
27. Anderson JJ, Baron G, van Der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001á44(8):1876-86
28. Brandt J, Listing J, Sieper J, et al. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004á63(11):1438-44
29. Lambert RG, Salonen D, Rahman P, et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: A multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2007á56(12):4005-14
30. van Der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006á54(7):2136-46
31. Davis JC Jr, Revicki D, van Der Heijde DM, et al. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study. Arthritis Rheum 2007á57(6):1050-7
32. Revicki DA, Luo MP, Wordsworth P, et al. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: Results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J Rheumatol 2008á35(7):1346-53
33. Maksymowych WP, Gooch KL, Wong RL, et al. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol 2010 37(2):385-92
34. Huang F, Gu J, Zhu P, et al. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: Results of a randomised, controlled trial. Ann Rheum Dis 2013
35. van Der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: Long-term results from the ATLAS trial. Ann Rheum Dis 2009á68(6):922-9
36. van Der Heijde DM, Revicki DA, Gooch KL, et al. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 2009á11(4):R124
37. van Der Heijde D, Breban M, Mease P, et al. Sustained clinical response and quality of life improvement through 4 years of adalimumab treatment in the ATLAS trial. Ann Rheum Dis 2009á68(Suppl3):624
38. Sieper J, van Der Heijde D, Dougados M, et al. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 2012á71(5):700-6
39. Machado P, Landewe R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): Defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2010 70(1):47-53
40. Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009á36(4):801- 8
41. Rudwaleit M, Gooch K, Michel B, et al. Adalimumab improves sleep and sleep quality in patients with active ankylosing spondylitis. J Rheumatol 2011á38(1):79-86
42. Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Ann Rheum Dis 2009á68(5):696-701
43. Rudwaleit M, Claudepierre P, Kron M, et al. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Arthritis Res Ther 2010 12(2):R43
44. Rudwaleit M, Van Den Bosch F, Kron M, et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 2010 12(3):R117
45. Conti F, Ceccarelli F, Marocchi E, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: An observational study over a 5-year period. Ann Rheum Dis 2007á66(10):1393-7
46. Haberhauer G, Strehblow C, Fasching P. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis. Wien Med Wochenschr 2010 160(9-10):220-4
47. Dadoun S, Geri G, Paternotte S, et al. Switching between tumour necrosis factor blockers in spondyloarthritis: A retrospective monocentre study of 222 patients. Clin Exp Rheumatol 2011á29(6):1010-13
48. Lie E, van Der Heijde D, Uhlig T, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: Data from the NOR-DMARD register. Ann Rheum Dis 2011á70(1):157-63
49. Horneff G, Fitter S, Foeldvari I, et al. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): Significant short term improvement. Arthritis Res Ther 2012á14(5):R230
50. van Der Heijde D, Pangan AL, Schiff MH, et al. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 2008á67(9):1218-21
51. Rudwaleit M, Olivieri I, Boki KA, et al. Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion. Rheumatology (Oxford) 2009á48(5):551-7
52. Maksymowych WP, Rahman P, Shojania K, et al. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 2008á35(10):2030-7
53. Pedersen SJ, Hetland ML, Sorensen IJ, et al. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFalpha inhibitors. Clin Rheumatol 2010 29(11):1301-9
54. Pedersen SJ, Sorensen IJ, Lambert RG, et al. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor alpha inhibitors: A study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. Arthritis Rheum 2011á63(12):3789-800
55. Hu Z, Xu M, Li Q, et al. Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis. Int J Rheum Dis 2012á15(4):358-65
56. Wanders A, Landewe R, Dougados M, et al. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: Can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 2005á64(7):988-94
57. Machado P, Landewe R, Braun J, et al. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 2010 69(8):1465-70
58. Landewe R, Dougados M, Mielants H, et al. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 2009á68(6):863-7
59. van Der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009á11(4):R127
60. van Der Heijde D, Landewe R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008á58(10):3063-70
61. van Der Heijde D, Landewe R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008á58(5):1324-31
62. Braun J, Baraliakos X, Hermann KG, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: Results through 4 years of the GO-RAISE trial. Ann Rheum Dis 2013
63. Maksymowych WP, Elewaut D, Schett G. Motion for debate: The development of ankylosis in ankylosing spondylitis is largely dependent on inflammation. Arthritis Rheum 2012á64(6):1713-19
64. Maksymowych WP, Morency N, Conner-Spady B, Lambert RG. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: Evidence for a window of opportunity in disease modification. Ann Rheum Dis 2013á72(1):23-8
65. Sieper J. Can structural damage be prevented in ankylosing spondylitis? Curr Opin Rheumatol 2009á21(4):335-9
66. Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2013
67. Haroon N, Inman RD, Learch TJ, et al. The Impact of TNF-inhibitors on radiographic progression in Ankylosing Spondylitis. Arthritis Rheum 2013
68. Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal antiinflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: Results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012á71(10):1616-22
69. Kroon F, Landewe R, Dougados M, van Der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012á71(10):1623-9
70. Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008á58(7):1981-91
71. Sieper J, van Der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: Results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013á72(6):815-22
72. EMA. Positive recommendations of Committee for Medicinal Products for Human Use (CHMP) on extensions of therapeutic indications for Humira (21 June 2012). Available from: Http:// www.emea.europa.eu/ema/pages/includes/ document/open-document.jsp? webContentId=WC500129074 [last accessed 20.05.2013
73. Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009á68(12):1863-9
74. Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013á72(4):517-24
75. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action. Arthritis Rheum 2008á59(7):996-1001
76. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010 40(3):233-40
77. Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitorinduced psoriasis or psoriasiform exanthemata: First 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008á9(1):1-14
78. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009á68(2):209-15
79. de Gannes GC, Ghoreishi M, Pope Jet al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007á143(2):223-31
80. Korsten P, Sweiss NJ, Nagorsnik U, et al. Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab. Am J Kidney Dis 2010 56(6):e17-21
81. Lunt M, Watson KD, Dixon WG, et al. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2010 62(11):3145-53
82. Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: Relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009á68(5):648-53
83. Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment? Arthritis Rheum 2009á60(11):3180-9
84. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010 12(1):R5
85. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011á50(1):124-31
86. Poddubnyy D, Rudwaleit M. Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Expert Opin Drug Saf 2011á10(4):655-73
87. Gaujoux-Viala C, Fautrel B. Cost effectiveness of therapeutic interventions in ankylosing spondylitis: A critical and systematic review. Pharmacoeconomics 2012á30(12):1145-56
88. Song IH, Poddubnyy D. New treatment targets in ankylosing spondylitis and other spondyloarthritides. Curr Opin Rheumatol 2011á23(4):346-51
89. Glintborg B, Ostergaard M, Krogh NS, et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: Results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010 69(11):2002-8
90. Baraliakos X, Listing J, Brandt J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005á7(3):R439-44